Almirall announces EMA acceptance for filing of Marketing Authorization Application (MAA) for…
Almirall, S.A. (ALM) announced that the European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for lebrikizumab for the treatment of…
Read More...
Read More...